Literature DB >> 14555244

The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline.

Moussa B H Youdim1, Tamar Amit, Merav Falach-Yogev, Orit Bar Am, Wakkako Maruyama, Makato Naoi.   

Abstract

The anti-Parkinson drug, rasagiline, a irreversible propargyl possessing monoamine oxidase B inhibitor can protect neurons in vitro and in vivo from a variety of neurotoxic insults including SIN-1, glutamate, the parkinsonism inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, N-methyl-(R)-salsolinol and including beta amyloid protein. Recent studies have shown that rasagiline rapidly modulates intracellular signaling pathways involved in cell survival and death. Specifically rasagiline activates Bcl-2, Bcl-xl, protein kinase C (PKC) and reduces Bax in a variety of cells including PC-12 and neuroblastoma human dopamine derived SH-SY5Y cells. These enzymes play key roles in cellular events including modulation of apoptotic processes, neuronal plasticity and amyloid precursor protein processing. This pharmacological action of rasagiline is also associated with the prevention of the neurotoxin induced fall in mitochondrial membrane potential, opening of mitochondria permeability transition pore, activation of proteasome-ubiquitin complex, inhibition of cytochrome c release and prevention of caspase 3 activation, similar to the actions of cyclosporin A or Bcl-2 over expression in SH-SY5Y cells. Rasagiline and its various derivatives induces PKC dependent release of soluble amyloid precursor protein alpha and which is blocked by inhibitors of alpha-secretase, PKC and MAPK-dependent signaling. Structure-activity relationship with various propargyl containing derivatives of rasagiline including propargylamine itself has shown that the above described pharmacological action of these compounds resides in the propargylamine moiety. These results have provided a new understanding into the mechanism of neuroprotective actions of rasagiline and its anti-Alzheimer drug derivatives TV3326 and TV3279, which are relevant for therapy of Parkinson's disease, Alzheimer's disease and other neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14555244     DOI: 10.1016/s0006-2952(03)00535-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  17 in total

1.  A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement.

Authors:  Zachary Macchi; Yunxia Wang; Dan Moore; Jonathan Katz; David Saperstein; David Walk; Ericka Simpson; Angela Genge; Tulio Bertorini; J Americo Fernandes; Andrea Swenson; Lauren Elman; Mazen Dimachkie; Laura Herbelin; Joann Miller; Jianghua Lu; Heather Wilkins; Russell H Swerdlow; Jeffrey Statland; Richard Barohn
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2015-04-02       Impact factor: 4.092

2.  Effects of CDNF on 6-OHDA-induced apoptosis in PC12 cells via modulation of Bcl-2/Bax and caspase-3 activation.

Authors:  Jia-Ming Mei; Chao-Shi Niu
Journal:  Neurol Sci       Date:  2014-03-15       Impact factor: 3.307

3.  Ginsenoside Rb1 protects cardiomyocytes against CoCl2-induced apoptosis in neonatal rats by inhibiting mitochondria permeability transition pore opening.

Authors:  Hong-liang Kong; Zhan-quan Li; Ying-jun Zhao; Shu-mei Zhao; Li Zhu; Tong Li; Yao Fu; Hui-jun Li
Journal:  Acta Pharmacol Sin       Date:  2010-06       Impact factor: 6.150

4.  N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2.

Authors:  H Yi; W Maruyama; Y Akao; T Takahashi; K Iwasa; M B H Youdim; M Naoi
Journal:  J Neural Transm (Vienna)       Date:  2005-04-22       Impact factor: 3.575

Review 5.  Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases.

Authors:  Russell H Swerdlow
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

Review 6.  Mitochondria in neurodegenerative disorders: regulation of the redox state and death signaling leading to neuronal death and survival.

Authors:  Makoto Naoi; Wakako Maruyama; Hong Yi; Keiko Inaba; Yukihiro Akao; Masayo Shamoto-Nagai
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

7.  Binge ethanol exposure increases the Krüppel-like factor 11-monoamine oxidase (MAO) pathway in rats: Examining the use of MAO inhibitors to prevent ethanol-induced brain injury.

Authors:  Jeremy W Duncan; Xiao Zhang; Niping Wang; Shakevia Johnson; Sharonda Harris; Chinelo Udemgba; Xiao-Ming Ou; Moussa B Youdim; Craig A Stockmeier; Jun Ming Wang
Journal:  Neuropharmacology       Date:  2016-01-22       Impact factor: 5.250

Review 8.  Recent developments in multiple system atrophy.

Authors:  Gregor K Wenning; Nadia Stefanova
Journal:  J Neurol       Date:  2009-05-27       Impact factor: 4.849

Review 9.  Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs.

Authors:  Orly Weinreb; Silvia Mandel; Orit Bar-Am; Merav Yogev-Falach; Yael Avramovich-Tirosh; Tamar Amit; Moussa B H Youdim
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

10.  TVP1022 protects neonatal rat ventricular myocytes against doxorubicin-induced functional derangements.

Authors:  Alexandra Berdichevski; Gideon Meiry; Felix Milman; Irena Reiter; Oshra Sedan; Sivan Eliyahu; Heather S Duffy; Moussa B Youdim; Ofer Binah
Journal:  J Pharmacol Exp Ther       Date:  2009-11-13       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.